Brigham Buhler, founder of Ways to Well and healthcare entrepreneur, joins Joe Rogan to discuss the latest developments in peptide regulation, stem cell therapy, and preventative medicine. Buhler has been working directly with the Kennedy administration and FDA leadership to establish regulatory pathways for peptides and biologics.

The conversation covers the current state of peptide regulation under the new administration, the safety profile of testosterone therapy, and emerging treatments like Muse stem cells. Buhler explains how medical dogma, as described in Blind Spot by FDA head Marty Makary, has prevented access to beneficial treatments while the current healthcare system focuses on managing chronic disease rather than preventing it.

They explore cutting-edge therapies including plasmapheresis, gene sequencing, and the potential for personalized medicine using AI and large language models. The discussion emphasizes the difference between the traditional insurance-based sick care system and emerging cash-pay preventative healthcare models.

FDA Peptide Reclassification Under Kennedy Administration

The Biden administration classified peptides as dangerous without providing safety data, despite Buhler submitting 17 FOIA requests that were never answered by the FDA.

Secretary Kennedy, Marty Makary (FDA head), and the new administration are working to restore peptide access through proper regulatory pathways with clinician oversight.

"Four out of five peptides being filled are being filled through gray or black market solutions" with no clinician in the chain of custody - Brigham.

The current unregulated environment represents "the most dangerous time it has ever been in the history of peptides" according to Buhler.

Testosterone Therapy Myths and FDA Black Box Warnings

All testosterone-prostate cancer fears stem from a 1930s study with three patients, where one dropped out and one was chemically castrated.

The FDA under new leadership is removing black box warnings on testosterone and hormone therapy, recognizing decades of debunked dogma.

"There is not one single study that correlates testosterone therapy to prostate cancer" despite millions of men using testosterone therapy - Brigham.

As described in Blind Spot, medical dogma often overrides scientific evidence, with groupthink being confused for consensus in academic medicine.

Big Pharma Lobbying and GLP-1 Market Dynamics

Eli Lilly increased their company value 7x to $800 billion, making GLP-1s "the biggest blockbuster molecule in the history of humanity" - Brigham.

The pharmaceutical industry spent $31 million in lobbying power last year, claiming compounders cost them $7 billion while the entire compounding sector only does $7 billion total.

HIMS allegedly set a "landmine" by violating patent laws in a Super Bowl ad, then inking a deal with Novo Nordisk within weeks, leading to antitrust lawsuits.

"The truth of the matter is, it's about $1.5 to $2 billion total that this industry was able to compound during the backlog" versus pharma's $35-40 billion annual GLP-1 revenue - Brigham.

Muse Stem Cells: The Next Generation of Regenerative Medicine

Muse stem cells, discovered by Mari Dozawa in 2010, are pluripotent cells that can differentiate into any damaged cell type through phagocytosis.

Unlike traditional MSCs with 3-5% engraftment rates, Muse cells achieve 15-30% engraftment and can pass the blood-brain barrier when administered intranasally.

"These cells will literally go into the body and take on the phenotype of any damaged cell" becoming young, healthy versions of damaged tissue - Brigham.

Muse cells showed 0% flu-like symptoms in trials versus 10-15% with traditional MSCs, and demonstrated non-tumorigenic properties even when treating pre-existing cancers.

A comatose patient in UAE, scheduled for organ harvest, began responding after Muse cell treatment, with brain function returning according to Buhler's account.

Gene Sequencing and Personalized Medicine Applications

Less than one in 1,000 people have had their genome sequenced despite 20,000 genes determining how the body's "software" operates.

Gordon Ryan's gene sequencing revealed a one-in-10-million tendon density gene and predispositions to staph infections and acidic gut health.

Future gene editing could create "eight times stronger bone mineral density" though recipients would have "excess sinking when swimming" due to increased density.

Ways to Well is integrating gene sequencing into their app using large language models to provide personalized treatment recommendations based on genetic predispositions.

Plasmapheresis and Microplastic Removal Protocols

Plasmapheresis removes 70% of inflammatory markers and toxins from blood, replacing plasma with healthy albumin in a process used for over 50 years.

Philip Franklin Lee's testosterone increased from 80-90 to 1,200 after microplastic removal and lifestyle changes, without testosterone therapy.

"We're going to take out 70% of all the bad stuff that's floating around in your blood" including BPCs, plasticizers, and endocrine disruptors - Brigham.

Ways to Well enhances traditional plasmapheresis by adding MSCs, peptides, and extracellular vesicles to the replacement albumin.

Cash-Pay Healthcare Model vs Traditional Insurance System

The traditional system resulted in "1.7 to 1.9 million Americans dying every year of chronic disease, more than every world war we've ever fought" - Brigham.

"The average American's on four or more prescription drugs" in a system designed as "prescription management" rather than healthcare.

Cash-pay models provide accountability since "if you don't produce for the patient, you're fired" unlike insurance models where patients can't choose providers.

Ways to Well aims to make concierge-level care affordable and scalable using AI, wearables, and large language models for real-time health tracking.